Clinical trials · Detroit, MI
Neoplasms clinical trials in Detroit
We’re tracking 98 recruiting neoplasms studies with a site in or near Detroit — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Detroit
- NCT07213804RecruitingPhase 3
Study of sofetabart mipitecan for ovarian cancer
This trial tests a new drug called sofetabart mipitecan for people with ovarian cancer that has come back after treatment. It is for those whose cancer is either resistant to platinum chemo (Part A) or sensitive to it (Parts B and C). The study will see if the drug can help shrink or slow the cancer.
Detroit, MichiganAges 18 years+ - NCT05023772Recruiting
Laser and targeted radiation for spine metastases
This trial tests a combination treatment that uses a laser and focused radiation to shrink tumors in the spine and help stabilize the area near the spinal cord. It’s meant for adults with certain types of solid cancers that have limited spread in the spine and who are not good candidates for surgery.
Detroit, MichiganAges 18 years+ - NCT01885299Recruiting
Long-term registry for stereotactic radiation treatments
This study collects long-term information from people who receive stereotactic radiosurgery or stereotactic body radiotherapy for tumors or other conditions. It helps researchers understand how these precise radiation treatments work over time.
Detroit, MichiganAges Any age - NCT06995898Recruiting
Blood test study for early cancer detection
This study is testing a new blood test that may help find cancer early. You will give blood samples over a year, and researchers will check them for signs of cancer.
Detroit, MichiganAges 45–75 - NCT06001788RecruitingPhase 1
Ziftomenib for relapsed or refractory acute myeloid leukemia
This trial tests a new drug combination called ziftomenib for people whose acute myeloid leukemia (AML) has come back or hasn't responded to treatment. Researchers will check how safe it is and what side effects happen.
Detroit, MichiganAges 18 years+ - NCT07173751RecruitingPhase 3
Pumitamig for advanced triple-negative breast cancer
This study tests a new drug called pumitamig for people with a type of breast cancer that is triple-negative or has very low hormone receptors and has come back or spread. It aims to see if pumitamig works better than standard treatment and how safe it is for people who cannot get PD(L)-1 immunotherapy with chemo.
Detroit, MichiganAges 18 years+ - NCT03435796RecruitingPhase 2/Phase 3
Follow-up for people treated with gene-modified T cells
This study is a long-term check-in for people who previously received gene-modified T-cell infusions in a related Celgene/Juno/BMS trial. It helps researchers track safety and long-term effects over time.
Detroit, MichiganAges Any age - NCT06925737RecruitingPhase 3
Study of I-DXd for metastatic prostate cancer
This study tests a new drug called Ifinatamab Deruxtecan (I-DXd) for people with metastatic prostate cancer that has stopped responding to hormone therapy. It may help by targeting and destroying cancer cells in a different way.
Detroit, MichiganAges 18 years+ - NCT06750094RecruitingPhase 3
Study of amivantamab plus FOLFIRI in colorectal cancer
This trial tests adding amivantamab to standard FOLFIRI chemotherapy for people with certain types of colorectal cancer that have already been treated once. It aims to see if this combination works better than another common treatment (cetuximab or bevacizumab plus FOLFIRI).
Detroit, MichiganAges 18 years+ - NCT07283939Recruiting
Testing a tool to adjust chemo doses and reduce treatment delays
This trial tests a computer algorithm called PAGODA that helps doctors adjust chemotherapy doses for people with gastrointestinal cancers. The goal is to prevent unplanned treatment delays while keeping the treatment effective.
Detroit, MichiganAges 18 years+ - NCT05711667RecruitingPhase 3
Letermovir to prevent CMV after stem cell transplant in kids
This trial tests whether the medicine letermovir can prevent a common virus (CMV) from coming back after an allogeneic stem cell transplant in children. It may help lower the risk of CMV infection during the vulnerable period right after transplant.
Detroit, MichiganAges 2–18 - NCT03866382RecruitingPhase 2
Immunotherapy plus a targeted drug for rare genitourinary tumors
This Phase 2 study tests whether nivolumab and ipilimumab (immunotherapy drugs) plus cabozantinib (a targeted anti-cancer drug) can shrink or control rare cancers of the urinary/reproductive system that have spread. It may help by boosting the immune system and blocking cancer growth signals at the same time.
Detroit, MichiganAges 18 years+ - NCT07214532Recruiting
Using a blood test to guide breast cancer therapy
This study tests whether a blood test can help decide when to start additional hormone-blocking therapy for early-stage breast cancer. It aims to see if starting therapy only when the test detects cancer DNA is as effective as giving it to everyone.
Detroit, MichiganAges 18 years+ - NCT01790152Recruiting
Dexrazoxane study to monitor heart damage in cancer survivors
This study tests dexrazoxane (DRZ) to see how it affects blood and heart-related “biomarkers,” or measurable signs of heart damage, after cancer treatment. It mainly targets survivors who may be at risk for cardiomyopathy (heart muscle weakness) or related heart failure.
Detroit, MichiganAges Any age - NCT07218380RecruitingPhase 3
Study of Vepugratinib for advanced bladder or urinary tract cancer
This trial tests an experimental drug called Vepugratinib for people with advanced urinary tract cancer that has a specific change in the FGFR3 gene. It may be an option if you haven't had other treatments for advanced cancer and are looking for a new approach.
Detroit, MichiganAges 18 years+ - NCT02402244Recruiting
Caring registry study for children and young people with cancer
This study keeps a careful record of children, teens, and young adults with cancer (and some related growths) and may follow them over time. It helps researchers better track outcomes and future contact so care can improve.
Detroit, MichiganAges Up to 25 years - NCT07198945Enrolling by invitation
6 vs 12 month follow-up after large colon polyp removal
This trial compares whether a follow-up colonoscopy at 6 or 12 months is better for people who have had a large polyp (20-50 mm) removed. It will help doctors understand the best timing for surveillance.
Detroit, MichiganAges 18 years+ - NCT06319820RecruitingPhase 3
TAR-210 vs standard bladder chemo for FGFR-mutated bladder cancer
This trial compares a new drug, TAR-210, which is placed directly into the bladder, against standard chemotherapy given through a catheter. It is for people with a specific type of bladder cancer that has a change in the FGFR gene.
Detroit, MichiganAges 18 years+ - NCT05386108RecruitingPhase 1/Phase 2
Test abemaciclib plus elacestrant for breast cancer brain spread
This trial studies whether the combination of abemaciclib and elacestrant can slow or shrink ER-positive, HER2-negative breast cancer that has spread to the brain. It is designed for people whose cancer has progressed despite prior hormone (endocrine) treatment.
Detroit, MichiganAges 18 years+ - NCT05614739RecruitingPhase 1
Study of vepugratinib for cancers with FGFR3 gene changes
This study tests a new pill, vepugratinib, for people whose cancer has a specific change in a gene called FGFR3. The drug targets this gene change to try to slow or shrink the cancer, and may be an option if standard treatments have not worked.
Detroit, MichiganAges 18 years+ - NCT03418961RecruitingPhase 3
Study of heart-risk management for metastatic HER2 breast cancer
This trial follows people with metastatic HER2-positive breast cancer who are at higher risk for heart damage while on HER2-targeted therapy. Some participants are randomly assigned to different monitoring/heart-protection approaches to see what best helps keep the heart safe.
Detroit, MichiganAges 18 years+ - NCT07213791RecruitingPhase 1
Study of a new drug for FAP-positive cancers
This trial tests a new drug (LY4337713) for cancers that have a specific protein called FAP on their surface. It may be an option for people whose cancer has continued to grow after standard treatments.
Detroit, MichiganAges 18 years+ - NCT05592626RecruitingPhase 1/Phase 2
T cell activator STAR0602 for advanced solid tumors
This study tests an experimental drug called STAR0602 that aims to boost your immune system's T cells to fight advanced solid tumors. It's for patients whose cancer has not responded to standard treatments or for whom such treatments are not suitable.
Detroit, MichiganAges 18 years+ - NCT06500481RecruitingPhase 3
Proton vs standard radiation for cancer spread to brain/spine lining
This trial compares a newer type of radiation (proton therapy) to standard radiation for people whose breast or lung cancer has spread to the lining of the brain and spinal cord. It aims to see if proton therapy can better control the disease while causing fewer side effects.
Detroit, MichiganAges 18 years+
Hear when a new Neoplasms trial opens near Detroit, MI
We’ll email you when one opens near Detroit, MI — at most once a week, no account needed, unsubscribe anytime.
Neoplasms trials in other cities
Where these studies are running near Detroit
Institutions with a site for the recruiting neoplasms studies listed above.
- Henry Ford Health · 11 studies
- Karmanos Cancer Institute · 9 studies
- Barbara Ann Karmanos Cancer Institute · 3 studies
- Hematology Oncology Consultants-Clarkston · 3 studies
- Henry Ford Macomb Hospital-Clinton Township · 3 studies
- Henry Ford Medical Center-Columbus · 3 studies
- Henry Ford Medical Center-Fairlane · 3 studies
- Henry Ford West Bloomfield Hospital · 3 studies
What taking part in a neoplasms study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting neoplasms studies in Michigan.
Common questions
- Are there neoplasms clinical trials near Detroit?
- Yes. We're currently tracking 98 recruiting neoplasms studies with a site near Detroit, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a neoplasms study near Detroit?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Detroit to take part?
- Not necessarily. These studies have a site near Detroit, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a neoplasms trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New neoplasms studies open near Detroit regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.